Fauci hopes U.S. regulators fully approve COVID-19 shots by mid-August By Reuters

2/2

© Reuters. Signs guide the public at a large vaccination and testing site as people with preexisting health conditions are granted access to a vaccination during the outbreak of the coronavirus disease (COVID-19) in Inglewood, California, U.S., March 15, 2021. REUT

2/2

NEW YORK (Reuters) – Top U.S. infectious disease expert Anthony Fauci said on Friday he hopes U.S. regulators could as soon as the middle of next month start granting full approval for the use of COVID-19 vaccines, which already are authorized on an emergency basis.

Formal approval by the U.S. Food and Drug Administration would give physicians the ability to prescribe a third dose of the COVID-19 vaccine to people with weakened immune systems on an off-label basis, Fauci said during an interview with Reuters.

Pfizer Inc (NYSE:) and BioNTech SE (NASDAQ:) as well as Moderna (NASDAQ:) Inc have filed with the FDA to ask for full approval for their two-dose vaccines. Johnson & Johnson (NYSE:) Inc has not yet requested full approval for its one-dose COVID-19 shot.

Fauci, the director of the National Institute of Allergy and Infectious Diseases and chief medical adviser to the White House, said full approval by the FDA could also help spur more Americans to get the COVID-19 vaccine as it might reduce their fears about the safety of the shot and make local officials more comfortable about implementing vaccine mandates.

“Given what we’ve been through now and the number of months that have gone by since the (emergency use authorization), I would hope that within the very reasonable period of time in the future we’ll see that. I hope as we get into the middle of August that we’re almost there,” he said.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Be the first to comment

Leave a Reply

Your email address will not be published.


*